Base-Modified Cytidine Nucleotides for Leukemia Therapy (EP3810140A1)
Summary
The European Patent Office published patent application EP3810140A1 for Medivir Aktiebolag covering base-modified cytidine nucleotides for leukemia therapy. The application includes IPC classifications for A61K 31/506 (pyrimidine derivatives), C07D 405/04 (heterocyclic compounds), and A61P 35/02 (antineoplastic agents). The patent designates all EPO member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.
What changed
The EPO published Medivir Aktiebolag's patent application EP3810140A1 for base-modified cytidine nucleotides as therapeutic agents for leukemia. The application claims priority compounds and methods for treating leukemia using modified nucleotide derivatives.
Pharmaceutical companies developing nucleotide-based therapeutics should monitor this publication for freedom-to-operate implications. The designation of all EPO member states means the patent, if granted, could provide broad European market exclusivity for leukemia therapies incorporating the claimed base-modified cytidine nucleotides.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BASE-MODIFIED CYTIDINE NUCLEOTIDES FOR LEUKEMIA THERAPY
Publication EP3810140A1 Kind: A1 Apr 08, 2026
Applicants
Medivir Aktiebolag
Inventors
PINHO, Pedro, KLASSON, Björn, ÖHD, John, ALBERTELLA, Mark
IPC Classifications
A61K 31/506 20060101AFI20191227BHEP C07D 405/04 20060101ALI20191227BHEP A61P 35/02 20060101ALI20191227BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.